IL135232A - 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids - Google Patents

21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids

Info

Publication number
IL135232A
IL135232A IL13523298A IL13523298A IL135232A IL 135232 A IL135232 A IL 135232A IL 13523298 A IL13523298 A IL 13523298A IL 13523298 A IL13523298 A IL 13523298A IL 135232 A IL135232 A IL 135232A
Authority
IL
Israel
Prior art keywords
oxidoprogesterone
glucocorticoids
hydroxy
treating excess
excess
Prior art date
Application number
IL13523298A
Other languages
English (en)
Other versions
IL135232A0 (en
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL135232A0 publication Critical patent/IL135232A0/xx
Publication of IL135232A publication Critical patent/IL135232A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13523298A 1997-09-23 1998-09-22 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids IL135232A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97116526A EP0903146A1 (fr) 1997-09-23 1997-09-23 21-Hydroy-6,19oxidoprogestérone (21-OH-60P) en tant qu'antiglucocorticoide
PCT/EP1998/006021 WO1999015181A1 (fr) 1997-09-23 1998-09-22 21-hydroxy-6,19-oxydoprogesterone(21oh-6op) et son utilisation en tant que medicament destine a traiter l'exces de glucocorticoides

Publications (2)

Publication Number Publication Date
IL135232A0 IL135232A0 (en) 2001-05-20
IL135232A true IL135232A (en) 2005-05-17

Family

ID=8227390

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13523298A IL135232A (en) 1997-09-23 1998-09-22 21-hydroxy-6 19-oxidoprogesterone for treating excess of glucocorticoids

Country Status (13)

Country Link
US (1) US6303591B1 (fr)
EP (2) EP0903146A1 (fr)
AR (1) AR023008A1 (fr)
AT (1) ATE215373T1 (fr)
AU (1) AU738522B2 (fr)
CA (1) CA2303817C (fr)
DE (1) DE69804659T2 (fr)
DK (1) DK1033990T3 (fr)
ES (1) ES2172937T3 (fr)
IL (1) IL135232A (fr)
PT (1) PT1033990E (fr)
WO (1) WO1999015181A1 (fr)
ZA (1) ZA988674B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL207610B1 (pl) 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
DK1330468T3 (da) * 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider
US7071328B2 (en) * 2000-09-18 2006-07-04 Applied Research System Ars Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op)
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
EP1886695A1 (fr) * 2006-06-27 2008-02-13 Speedel Experimenta AG Combinaisons pharmacéutiques avec inhibiteurs de l'aldosterone synthase et antagonistes du recepteur de glucocorticoides où inhibiteurs de la synthese de cortisol où antagonistes du facteur de libération de la corticotropine
AU2007287070C1 (en) 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
WO2011150209A1 (fr) 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Traitement de la dystrophie musculaire
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP3733170A1 (fr) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. Procédé de traitement de cancers du sein positifs aux récepteurs des androgène (ar) à l'aide d'un modulateur sélectif des récepteurs androgènes (sarm)
JP6821582B2 (ja) 2015-03-02 2021-01-27 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
JP6754533B2 (ja) 2015-03-30 2020-09-16 コーセプト セラピューティクス， インコーポレイテッド 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用
MX383318B (es) 2015-08-13 2025-03-13 Corcept Therapeutics Inc Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
JP6765443B2 (ja) 2016-01-19 2020-10-07 コーセプト セラピューティクス， インコーポレイテッド 異所性クッシング症候群の鑑別診断
WO2018236749A2 (fr) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Méthodes de traitement des tumeurs neuro-épithéliales à l'aide de modulateurs sélectifs du récepteur de glucocorticoïdes
CN113645979A (zh) * 2018-12-28 2021-11-12 熊猫咨询有限责任公司 短效选择性糖皮质激素受体调节剂
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction

Also Published As

Publication number Publication date
AU738522B2 (en) 2001-09-20
PT1033990E (pt) 2002-07-31
US6303591B1 (en) 2001-10-16
IL135232A0 (en) 2001-05-20
CA2303817A1 (fr) 1999-04-01
DE69804659T2 (de) 2002-10-02
WO1999015181A1 (fr) 1999-04-01
ATE215373T1 (de) 2002-04-15
EP1033990B1 (fr) 2002-04-03
EP1033990A1 (fr) 2000-09-13
ES2172937T3 (es) 2002-10-01
EP0903146A1 (fr) 1999-03-24
AR023008A1 (es) 2002-09-04
AU1334199A (en) 1999-04-12
ZA988674B (en) 1999-06-28
CA2303817C (fr) 2008-04-01
DK1033990T3 (da) 2002-07-08
DE69804659D1 (de) 2002-05-08

Similar Documents

Publication Publication Date Title
IL135232A0 (en) 21-hydroxy-6, 19-oxidoprogesterone for treating excess of glucocorticoids
EP0874828A4 (fr) Compositions de traitement de la douleur
IL131484A0 (en) Treatment of cardiomyopathy
AP9600840A0 (en) Treatment of ovarian estrogen dependent conditions
AU7582398A (en) Composition for treating skin conditions
PL338082A1 (en) Methods of treating obesity
IL120262A0 (en) Method of increasing testosterone
IL136515A0 (en) Combination effective for the treatment of impotence
GB9715295D0 (en) Novel method of treatment
GB9712866D0 (en) Novel method of treatment
GB9707693D0 (en) Novel method of treatment
GB9725114D0 (en) Treatment of pruritus
GB9715298D0 (en) Novel method of treatment
GB9715306D0 (en) Novel method of treatment
IL124419A0 (en) Composition for treating pain
PL341667A1 (en) Method of treating cooped
PL334803A1 (en) Derivatives of imino-aza-antracyclinone for treating amyloidosis
EP1007041A4 (fr) Composition analgesique
PL340430A1 (en) Combination for treating aids
AU7247898A (en) Composition for treating pain
PL335904A1 (en) Application of 7alpha-methyl-17alpha-ethynylestrane derivative for treating arteriosclerosis
EP0912178A4 (fr) Methodes de traitement de l'hypertension
IL120254A0 (en) Composition for treatment of acne
PL327430A1 (en) Set of shaped components
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides

Legal Events

Date Code Title Description
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
MM9K Patent not in force due to non-payment of renewal fees